These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 27226628)

  • 1. A Camelid-derived Antibody Fragment Targeting the Active Site of a Serine Protease Balances between Inhibitor and Substrate Behavior.
    Kromann-Hansen T; Oldenburg E; Yung KW; Ghassabeh GH; Muyldermans S; Declerck PJ; Huang M; Andreasen PA; Ngo JC
    J Biol Chem; 2016 Jul; 291(29):15156-68. PubMed ID: 27226628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a novel conformational equilibrium in urokinase-type plasminogen activator.
    Kromann-Hansen T; Louise Lange E; Peter Sørensen H; Hassanzadeh-Ghassabeh G; Huang M; Jensen JK; Muyldermans S; Declerck PJ; Komives EA; Andreasen PA
    Sci Rep; 2017 Jun; 7(1):3385. PubMed ID: 28611361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insights into the serine protease mechanism based on structural observations of the conversion of a peptidyl serine protease inhibitor to a substrate.
    Jiang L; Andersen LM; Andreasen PA; Chen L; Huang M
    Biochim Biophys Acta; 2016 Mar; 1860(3):599-606. PubMed ID: 26691138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanistic analysis of allosteric and non-allosteric effects arising from nanobody binding to two epitopes of the dihydrofolate reductase of Escherichia coli.
    Oyen D; Wechselberger R; Srinivasan V; Steyaert J; Barlow JN
    Biochim Biophys Acta; 2013 Oct; 1834(10):2147-57. PubMed ID: 23911607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unraveling the allosteric mechanism of serine protease inhibition by an antibody.
    Ganesan R; Eigenbrot C; Wu Y; Liang WC; Shia S; Lipari MT; Kirchhofer D
    Structure; 2009 Dec; 17(12):1614-1624. PubMed ID: 20004165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural and mechanistic insight into how antibodies inhibit serine proteases.
    Ganesan R; Eigenbrot C; Kirchhofer D
    Biochem J; 2010 Sep; 430(2):179-89. PubMed ID: 20704569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cleavage of peptidic inhibitors by target protease is caused by peptide conformational transition.
    Jiang L; Oldenburg E; Kromann-Hansen T; Xu P; Jensen JK; Andreasen PA; Huang M
    Biochim Biophys Acta Gen Subj; 2018 Sep; 1862(9):2017-2023. PubMed ID: 29959058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure of an affinity-matured inhibitory recombinant fab against urokinase plasminogen activator reveals basis of potency and specificity.
    Sevillano N; Bohn MF; Zimanyi M; Chen Y; Petzold C; Gupta S; Ralston CY; Craik CS
    Biochim Biophys Acta Proteins Proteom; 2021 Feb; 1869(2):140562. PubMed ID: 33221341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.
    Katz BA; Elrod K; Luong C; Rice MJ; Mackman RL; Sprengeler PA; Spencer J; Hataye J; Janc J; Link J; Litvak J; Rai R; Rice K; Sideris S; Verner E; Young W
    J Mol Biol; 2001 Apr; 307(5):1451-86. PubMed ID: 11292354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structures of a llama VHH antibody BCD090-M2 targeting human ErbB3 receptor.
    Eliseev IE; Yudenko AN; Vysochinskaya VV; Svirina AA; Evstratyeva AV; Drozhzhachih MS; Krendeleva EA; Vladimirova AK; Nemankin TA; Ekimova VM; Ulitin AB; Lomovskaya MI; Yakovlev PA; Bukatin AS; Knyazev NA; Moiseenko FV; Chakchir OB
    F1000Res; 2018; 7():57. PubMed ID: 30430004
    [No Abstract]   [Full Text] [Related]  

  • 11. A structural mechanism of flavonoids in inhibiting serine proteases.
    Xue G; Gong L; Yuan C; Xu M; Wang X; Jiang L; Huang M
    Food Funct; 2017 Jul; 8(7):2437-2443. PubMed ID: 28644504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of ligand exchange kinetics via active-site trapping with an antibody fragment.
    Oyen D; Steyaert J; Barlow JN
    Biochemistry; 2014 Apr; 53(12):1879-81. PubMed ID: 24617671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors.
    Katz BA; Elrod K; Verner E; Mackman RL; Luong C; Shrader WD; Sendzik M; Spencer JR; Sprengeler PA; Kolesnikov A; Tai VW; Hui HC; Breitenbucher JG; Allen D; Janc JW
    J Mol Biol; 2003 May; 329(1):93-120. PubMed ID: 12742021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure of an Fab-protease complex reveals a highly specific non-canonical mechanism of inhibition.
    Farady CJ; Egea PF; Schneider EL; Darragh MR; Craik CS
    J Mol Biol; 2008 Jul; 380(2):351-60. PubMed ID: 18514224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigen recognition by single-domain antibodies: structural latitudes and constraints.
    Henry KA; MacKenzie CR
    MAbs; 2018; 10(6):815-826. PubMed ID: 29916758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B.
    Shia S; Stamos J; Kirchhofer D; Fan B; Wu J; Corpuz RT; Santell L; Lazarus RA; Eigenbrot C
    J Mol Biol; 2005 Mar; 346(5):1335-49. PubMed ID: 15713485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structures of native and complexed complement factor D: implications of the atypical His57 conformation and self-inhibitory loop in the regulation of specific serine protease activity.
    Jing H; Babu YS; Moore D; Kilpatrick JM; Liu XY; Volanakis JE; Narayana SV
    J Mol Biol; 1998 Oct; 282(5):1061-81. PubMed ID: 9753554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A general strategy to inhibit serine protease by targeting its autolysis loop.
    Jiang L; Yuan C; Huang M
    FASEB J; 2021 Feb; 35(2):e21259. PubMed ID: 33417271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The crystal structure of the catalytic domain of human urokinase-type plasminogen activator.
    Spraggon G; Phillips C; Nowak UK; Ponting CP; Saunders D; Dobson CM; Stuart DI; Jones EY
    Structure; 1995 Jul; 3(7):681-91. PubMed ID: 8591045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection of High-Affinity Peptidic Serine Protease Inhibitors with Increased Binding Entropy from a Back-Flip Library of Peptide-Protease Fusions.
    Sørensen HP; Xu P; Jiang L; Kromann-Hansen T; Jensen KJ; Huang M; Andreasen PA
    J Mol Biol; 2015 Sep; 427(19):3110-22. PubMed ID: 26281711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.